Yale Mitchel - Concepedia

Author

Yale Mitchel

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

B Mihaylova, Bruce Ovbiagele, G. Moen, P DeLucca, S. Rodriguez-Cuenca, Y B Mitchel, Y Mitchel, Y. B. Mitchel, Y. Mitchel, Y.B Mitchel

109

Publications

5.8K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Louisville Metabolic and Atherosclerosis Research Center Baylor College of Medicine National Clinical Research Center for Clinical Research (United States)

About

Yale Mitchel is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, cardiovascular disease, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	39	2.7K
2	Public Health	6	6	425
3	Biochemistry	2	2	85
4	Health Sciences	1	1	54
5	Anesthesia	1	1	14

Yale Mitchel

Publications

4.5K

Citations

H-Index

Page 1

	Year	Citations
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease Christopher P. Cannon, Sukrut Shah, Hayes M. Dansky, New England Journal of Medicine	2010	746
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Daniel M. Bloomfield, Gary L. Carlson, Aditi Sapre, American Heart Journal Lipid DisorderCardiovascular DiseaseMedicineDyslipidemic PatientsCardiovascular Pharmacology	2008	242
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention Erin A. Bohula, David A. Morrow, Robert P. Giugliano, Journal of the American College of Cardiology ThrombosisVenous ThrombosisCardiovascular DiseaseMedicineSecondary Prevention	2017	196
Efficacy and Safety of Ezetimibe Coadministered With Simvastatin in Patients With Primary Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial Anne C. Goldberg, Aditi Sapre, Ji Liu, Mayo Clinic Proceedings Primary HypercholesterolemiaLipid DisorderCardiovascular DiseaseMedicinePlacebo-controlled Trial	2004	193
Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without the Metabolic Syndrome Kalevi Pyörälà, Christie M. Ballantyne, Barry Gumbiner, Diabetes Care	2004	168
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia Michel Farnier, Mason W. Freeman, Geraldine Macdonell, European Heart Journal	2005	162
Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix. John F. Paolini, Yale Mitchel, Robert Reyes, The American Journal of Cardiology Lipid DisorderStudy InvestigatorsCardiovascular DiseaseNicotinePharmacology	2007	161
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616 Christie M. Ballantyne, Puja Banka, Gustavo Méndez, Journal of the American College of Cardiology	2023	160
Treatment of High-Risk patients with ezetimibe plus simvastatin Co-Administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals Theodore Feldman, Michael J. Koren, William Insull, The American Journal of Cardiology Health PolicyCardiovascular DiseaseHyperlipidemiaDyslipidemiaHigh-risk Patients	2004	138
Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression Brett Lauring, Andrew K.P. Taggart, James R. Tata, Science Translational Medicine	2012	125

Page 1